Jenex

Jenex is a medical technology company primarily known for the development and commercialization of the Intercept CS, a proprietary medical device designed for the prevention and treatment of cold sores (Herpes Labialis). The device utilizes controlled thermal therapy to interfere with the replication of the Herpes Simplex Virus 1 (HSV-1) at the site of an outbreak, providing a non-pharmaceutical alternative to traditional topical and oral antiviral treatments. While the Intercept CS received regulatory clearances from the FDA and Health Canada, the company has faced significant financial and operational challenges in recent years. Currently, Jenex is listed on the NEX board of the TSX Venture Exchange, reflecting its status as a shell company exploring strategic alternatives or a potential change of business.